Loading...
Kala Pharmaceuticals, Inc.
KALA•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$8.09
$1.09(15.57%)
Kala Pharmaceuticals, Inc. (KALA) Financial Performance & Income Statement Overview
Review Kala Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-4.67%
↓ 4.67%
Net Income Growth
8.74%
↑ 8.74%
Operating Cash Flow Growth
-5.21%
↓ 5.21%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-369.29%
↓ 369.29%
ROIC
-157.14%
↓ 157.14%
Kala Pharmaceuticals, Inc. (KALA) Income Statement & Financial Overview
Review Kala Pharmaceuticals, Inc.'s (KALA) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $61000.00 | $66000.00 |
| Gross Profit | $0.00 | $0.00 | -$61000.00 | -$66000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $5.19M | $5.17M | $5.32M | $6.35M |
| SG&A Expenses | $4.20M | $4.40M | $4.32M | $5.36M |
| Operating Expenses | $9.46M | $9.99M | $9.57M | $11.71M |
| Total Costs & Expenses | $9.46M | $9.99M | $9.63M | $11.77M |
| Interest Income | $478000.00 | $570000.00 | $504000.00 | $504000.00 |
| Interest Expense | $1.39M | $1.48M | $1.46M | $1.46M |
| Depreciation & Amortization | $69000.00 | $63000.00 | $61000.00 | $66000.00 |
| EBITDA | -$6.71M | -$7.41M | -$8.06M | -$10.29M |
| EBITDA Ratio | ||||
| Operating Income | -$9.46M | -$9.99M | -$9.61M | -$11.77M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $1.28M | $1.04M | $26000.00 | -$34000.00 |
| Income Before Tax | -$8.18M | -$8.95M | -$9.58M | -$11.81M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $22724.00 |
| Net Income | -$8.18M | -$8.95M | -$9.58M | -$11.81M |
| Net Income Ratio | ||||
| EPS | -$1.74 | -$1.93 | -$3.16 | -$4.20 |
| Diluted EPS | -$1.74 | -$1.93 | -$3.16 | -$4.20 |
| Weighted Avg Shares Outstanding | $4.69M | $4.63M | $3.03M | $2.81M |
| Weighted Avg Shares Outstanding (Diluted) | $4.69M | $4.63M | $3.03M | $2.81M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan